At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 108 enrolled
Drug / intervention
VK5211 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture
In Brief
A Phase 2 clinical trial evaluating VK5211 and Placebo for Hip Fractures. Completed, enrolled 108 participants across 21 sites in 4 countries.
Detailed Summary
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fractures
CountriesHungary, Romania, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionNov 2017
Study CompletionDec 2017
TodayJul 2026
First PostedOct 16, 2015
Enrollment StartOct 30, 2015
Primary CompletionNov 15, 2017
Study CompletionDec 17, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.7 years ago
Interventions
VK5211drug
Capsule
Placebodrug
Capsule